Goldman Sachs’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Goldman Sachs’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-543,200	Closed	-$29M	–	7598
2016 Q1	$29M	Buy	543,200 +313,200	+136%	+$23.1M	0.01%	1448
2015 Q4	$26M	Buy	230,000 +78,200	+52%	+$8.61M	0.01%	1569
2015 Q3	$17.9M	Buy	151,800 +114,300	+305%	+$14.9M	0.01%	1792
2015 Q2	$2.9M	Buy	37,500 +25,700	+218%	+$1.68M	﹤0.01%	3471
2015 Q1	$683K	Buy	+11,800	New	+$501K	﹤0.01%	4827
2013 Q3	–	Sell	-5,000	Closed	-$28K	–	6936
2013 Q2	$28K	Buy	+5,000	New	+$30.3K	﹤0.01%	6154

Other funds holding ANAC

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Goldman Sachs's ANAC Position: Q2 2016 in Review

Goldman Sachs sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 1,561,729 shares — an estimated $83.5M sold.

Goldman Sachs first reported a position in ANAC in Q2 2013 and held it in 10 quarters. The position peaked at $83.5M in Q1 2016. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

Goldman Sachs reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
Goldman Sachs sold 1,561,729 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $83.5M.
Goldman Sachs first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 10 quarters.
Goldman Sachs's ANACOR PHARMACEUTICALS INC COM position peaked at $83.5M in Q1 2016.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Goldman Sachs's 13F filing for Q2 2016, filed 15 Aug 2016.